Advertisement

Topics

Johns Hopkins Medicine, Maryland Stem Cell Research Fund and BioCardia Announce First Patient Treated with CardiAMP Cell Therapy for Ischemic Heart Failure in Phase III Clinical Trial

08:00 EST 28 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Johns Hopkins Medicine, the Maryland Stem Cell Research Fund (MSCRF) and BioCardia, Inc. (OTC:BCDA) today announced that the first patient has been treated in the pivotal Phase III CardiAMP® clinical trial of a cell-based thera...

Other Sources for this Article

For BioCardia
Media Contact:
Michelle McAdam, Chronic Communications, Inc.
michelle@chronic-comm.com
(310) 545-6654
or
Investor Contact:
David McClung, Vice President Finance & CFO
investors@BioCardia.com
(650) 226-0120
or
For Johns Hopkins
Media Contact:
Vanessa McMains, Sr. Media Relations Representative
vmcmain1@jhmi.edu
(410) 502-9410
or
For Maryland Stem Cell Research Fund
Media Contact:
Tammi Thomas, VP of Marketing TEDCO
tthomas@tedco.md
(410) 715-4162

NEXT ARTICLE

More From BioPortfolio on "Johns Hopkins Medicine, Maryland Stem Cell Research Fund and BioCardia Announce First Patient Treated with CardiAMP Cell Therapy for Ischemic Heart Failure in Phase III Clinical Trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...